The FDA has approved olaparib (LynparzaTM, AstraZeneca Pharmaceuticals LP) for adult patients with homologous recombination repair (HRR)–mutated metastatic castration-resistant prostate cancer (CRPC) who experience disease progression after treatment with enzalutamide or abiraterone acetate. In addition, the FDA approved two companion diagnostic devices: FoundationOne® CDx (Foundation Medicine, Inc.), for the identification of HRR gene alterations, and BRACAnalysis CDx®(Myriad Genetics, Inc...

The FDA has granted accelerated approval to rucaparib (Rubraca®, Clovis Oncology, Inc.) for patients with deleterious germline and/or somatic BRCA-mutated metastatic castration-resistant prostate cancer (CRPC) who have previously received one line of taxane-based chemotherapy and one or more lines of androgen receptor-directed therapy.The approval was based on TRITON2 (NCT02952534), a phase 2 clinical trial which enrolled 115 patients with BRCA-mutated metastatic CRPC. Patients received 600 mg o...

Results from a multicenter, randomized study (ANZCTR12617000005358) have shown that prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) has superior efficacy in staging men with high-risk localized prostate cancer compared with conventional imaging using computed tomography (CT) and bone scan. In an interview with i3 Health, lead investigator from the study, Michael Hofman, MBBS, discusses challenges of treating patients with high-risk prostate can...

Low-grade prostate cancers have a much lower risk of cancer-specific death, while high-grade prostate cancers account for the majority of deaths from prostate cancer; therefore, precise diagnosis is of utmost importance. In order to achieve a high rate of accurate detection of this disease, standard biopsy in conjunction with magnetic resonance imaging (MRI) is necessary. A recent study found that when used together, these two techniques are more effective in targeting and sampling suspicious pr...

Men with metastatic castration-sensitive prostate cancer (CSPC) generally experience an initial response to androgen deprivation therapy (ADT), but with time, the cancer invariably becomes castration resistant. A new analysis of data from the phase 3 CHAARTED trial, published last week in JAMA Oncology, shows that men with low-volume metastatic CSPC who have the adrenal-permissive genotype of the HSD3B1 gene experience more rapid progression to castration-resistant disease and shorter overall su...